title: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
abstract: Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (chi-squared for trend=11.3, P<0.001; r2=0.86, P<0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates (P=0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
authors.affiliation: Department of Hematology, University Hospital and Regional Oncology Centre, Linköping, Sweden. Gunnar.Juliusson@med.lu.se
authors.forename: G
authors.initials: G
authors.lastname: Juliusson
authors.forename: R
authors.initials: R
authors.lastname: Billström
authors.forename: A
authors.initials: A
authors.lastname: Gruber
authors.forename: E
authors.initials: E
authors.lastname: Hellström-Lindberg
authors.forename: M
authors.initials: M
authors.lastname: Höglunds
authors.forename: K
authors.initials: K
authors.lastname: Karlsson
authors.forename: D
authors.initials: D
authors.lastname: Stockelberg
authors.forename: A
authors.initials: A
authors.lastname: Wahlin
authors.forename: M
authors.initials: M
authors.lastname: Aström
authors.forename: C
authors.initials: C
authors.lastname: Arnesson
authors.forename: U
authors.initials: U
authors.lastname: Brunell-Abrahamsson
authors.forename: J
authors.initials: J
authors.lastname: Carstensen
authors.forename: E
authors.initials: E
authors.lastname: Fredriksson
authors.forename: E
authors.initials: E
authors.lastname: Holmberg
authors.forename: K
authors.initials: K
authors.lastname: Nordenskjöld
authors.forename: F
authors.initials: F
authors.lastname: Wiklund
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001291:Attitude of Health Personnel; D005500:Follow-Up Studies; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D018579:Patient Selection; D012042:Registries; D012074:Remission Induction; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology; D016896:Treatment Outcome